AFM13 monotherapy was well tolerated and reached an Objective Response Rate of 42 percent among heavily pretreated patients with R/R CD30-positive lymphoma with cutaneous presentation Immunological ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results